Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SaTX-3
- Development stage
- Preclinical
- Lead developer
- StarkAge Therapeutics
01
Overview
SaTX-3 is an early-stage therapeutic candidate being developed by StarkAge Therapeutics. It is part of a discovery-stage program focused on identifying and destroying senescent cells, a therapeutic approach known as senolysis. Senescent cells are cells that have ceased dividing but remain metabolically active, often secreting pro-inflammatory factors that contribute to aging and various pathologies. SaTX-3 is intended for the treatment of cancer and other senescence-related conditions. While the specific molecular target and modality remain undisclosed, the program leverages StarkAge's platform for identifying novel biomarkers of senescent cells to selectively eliminate them while sparing healthy tissue.
Beyond the preview
Go deeper on SaTX-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SaTX-3.